

AD-HOC ANNOUNCEMENT

(pursuant to section 15 WpHG)

MeVis Medical Solutions AG Caroline-Herschel-Strasse 1 28359 Bremen Germany

Phone: +49 421 224 95 0 Fax: +49 421 224 95 999 E-mail: ir@mevis.de

Agreement on the conclusion of a domination agreement between VMS Deutschland Holdings GmbH and MeVis Medical Solutions AG

Bremen, April 29, 2015 – The management of VMS Deutschland Holdings GmbH, Darmstadt, and the Executive Board of MeVis Medical Solutions AG [ISIN: DE000A0LBFE4] have agreed today to prepare and to close a domination agreement between VMS Deutschland Holdings GmbH as controlling company and MeVis Medical Solutions AG as controlled company. The cash compensation and guaranteed dividend for minority shareholders of MeVis Medical Solutions AG will be determined in accordance with the statutory requirements and on the basis of a pending evaluation of the company. In order to become effective, the intended domination agreement requires the approval of the general shareholders' meeting of MeVis Medical Solutions AG, which will be scheduled in the second half of the year.

VMS Deutschland Holdings GmbH, an affiliate of Varian Medical Systems, Inc., Palo Alto, California, USA, published a voluntary public takeover offer on January 27, 2015 to all shareholders of MeVis Medical Solutions AG to acquire their registered non-par value shares against payment of 17.50 Euros per share. The offer was accepted for 1,337,995 shares (representing 73.52 % of the total share capital). The settlement of the offer was completed on April 21, 2015, so that VMS Deutschland Holdings GmbH acquired on this date the majority of shares in MeVis Medical Solutions AG.

MeVis Medical Solutions AG was founded in 1997 and is one of the world's leading independent developer and provider of medical imaging software with focus on dedicated, disease-oriented clinical applications. MeVis AG has been listed on the Frankfurt Stock Exchange in the Prime Standard segment of the Regulated Market since November 16, 2007.

Over the past few years, there has been an enormous increase in the complexity and volume of medical imaging data derived from diagnostic imaging processes such as digital mammography, computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound (US). MeVis' products analyze and process this data in such a way as to provide medical professionals with crucial information for early detection, diagnosis and intervention in the areas of cancer and lung diseases as well as neurological disorders. The Company develops its software solutions in close consultation with world's leading medical experts and original equipment manufacturers (OEM) in the medical technology sector and primarily markets this software via these partnerships.